http://repository.iphce.org/xmlui/handle/123456789/5312 Wed, 20 May 2026 18:18:38 GMT 2026-05-20T18:18:38Z http://repository.iphce.org/xmlui/handle/123456789/5371 Peer-led HIV care and the UNAIDS 90-90-90 treatment targets in Sidama Ethiopia: A cluster randomized trial and economic evaluation of Teach-Test- Link-Trace model (TTLT) trial Ethiopian Food and Drug Authority This study aims to test a new and comprehensive intervention program, never been implemented in Ethiopia before, called the teach-test-link-trace (TTLT) model. The TTLT model involves HIV positive volunteer patients (peer educators) who do HIV counselling (teach), perform HIV testing (test) through HIV self-testing (HIVST) and house-to-house HIV testing (H2H), link HIV positive patients to HIV care (link) and trace lost patients house-to- house (trace). Wed, 01 Jan 2025 00:00:00 GMT http://repository.iphce.org/xmlui/handle/123456789/5371 2025-01-01T00:00:00Z http://repository.iphce.org/xmlui/handle/123456789/5369 A revised Tafenoquine dose to improve radical cure for Vivax malaria -Tafenoquine dosing revised Ethiopian Food and Drug Authority Tafenoquine (TQ), as a single dose regimen, has significant advantages over the longer courses of primaquine (PQ) needed to achieve radical cure of P. vivax. The current data available show that the recommended fixed dose of 300mg TQ in adults is too low and compromised by a lack of weight-based dosing. To ensure maximal impact on health outcomes, the recommended dose for TQ must be optimized for clinical practice. Our study will assess the efficacy and safety of a higher weight based TQ dose regimen. Mon, 01 Jan 2024 00:00:00 GMT http://repository.iphce.org/xmlui/handle/123456789/5369 2024-01-01T00:00:00Z http://repository.iphce.org/xmlui/handle/123456789/5367 Serological testing and treatment for plasmodium vivax malaria: A cluster-randomized trial in Ethiopia Ethiopian Food and Drug Authority The resilience of P. vivax to malaria elimination efforts is due to its ability to form dormant liver stages (hypnozoites) that reactivate weeks to months after the initial infection causing recurrent episodes of malaria (relapses) and ongoing parasite transmission. Relapses account for 60-90% of recurrent infections and clinical cases of P. vivax malaria, and therefore have a significant effect on morbidity at the individual level. Wed, 01 Jan 2025 00:00:00 GMT http://repository.iphce.org/xmlui/handle/123456789/5367 2025-01-01T00:00:00Z http://repository.iphce.org/xmlui/handle/123456789/5366 Pharmacovigilance newsletter Ethiopian Food and Drug Authority The Ethiopian Food and Drug Authority in collaboration with its partners, successfully conducted a four-day Pharmacovigilance Data Management and Analysis Training from July 17–20, 2025, in Adama Town, Ethiopia. The training brought together Pharmacovigilance experts working at the national centre to enhance their technical capacity in monitoring medicine and vaccine safety. Wed, 01 Jan 2025 00:00:00 GMT http://repository.iphce.org/xmlui/handle/123456789/5366 2025-01-01T00:00:00Z